Ensembl ID ENSG00000100393 Gene ID 2033 Accession 3373
Gene Symbol EP300 Alias p300;KAT3B;MKHK2;RSTS2 Full Name E1A binding protein p300
Position 22 : 41092592 - 41180077 Length 87486 bases Strand Plus strand
Status Confidence Main interacting RNAsN.A.RBP type Canonical_RBPs
Summary This gene encodes the adenovirus E1A-associated cellular p300 transcriptional co-activator protein. It functions as histone acetyltransferase that regulates transcription via chromatin remodeling and is important in the processes of cell proliferation and differentiation. It mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. This gene has also been identified as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and thus plays a role in the stimulation of hypoxia-induced genes such as VEGF. Defects in this gene are a cause of Rubinstein-Taybi syndrome and may also play a role in epithelial cancer. [provided by RefSeq, Jul 2008]

ENSG00000100393 Expression In 33 Tumors

Ensembl ID Gene symbol Log2 Foldchange Pvaue Cancer
Ensembl ID Gene symbol Cancer types Pubmed ID
ENSG00000100393 EP300 cancers 10700188
ENSG00000100393 EP300 tumour 12385008
ENSG00000100393 EP300 cancer 12696060
ENSG00000100393 EP300 astrocytic tumors 14712485
ENSG00000100393 EP300 colorectal cancer 15217503
ENSG00000100393 EP300 cancer 16638127
ENSG00000100393 EP300 familial breast cancer 16704985
ENSG00000100393 EP300 prostate cancer 17627840
ENSG00000100393 EP300 tumor 17925008
ENSG00000100393 EP300 breast cancer 17962304
ENSG00000100393 EP300 breast cancer 19183483
ENSG00000100393 EP300 pituitary tumor 19539243
ENSG00000100393 EP300 tumor 19569050
ENSG00000100393 EP300 breast cancer 19996301
ENSG00000100393 EP300 tumors 21212384
ENSG00000100393 EP300 tumors 21390126
ENSG00000100393 EP300 tumor 21489305
ENSG00000100393 EP300 DLBCL 21796119
ENSG00000100393 EP300 GBM 21807073
ENSG00000100393 EP300 breast cancer 21857970
ENSG00000100393 EP300 tumour 21923952
ENSG00000100393 EP300 bladder cancer 21935574
ENSG00000100393 EP300 AML 22371884
ENSG00000100393 EP300 tumors 22459148
ENSG00000100393 EP300 cancer 22518120
ENSG00000100393 EP300 cancer 22709982
ENSG00000100393 EP300 GBM 22829753
ENSG00000100393 EP300 endometrial cancer 22876322
ENSG00000100393 EP300 cancer 22984806
ENSG00000100393 EP300 lung cancer 23269275
ENSG00000100393 EP300 tumor 23389039
ENSG00000100393 EP300 cancer 23554959
ENSG00000100393 EP300 AML 23559008
ENSG00000100393 EP300 tumor 23698071
ENSG00000100393 EP300 tumor 23759652
ENSG00000100393 EP300 squamous cell lung cancer 23799614
ENSG00000100393 EP300 cancer 24063517
ENSG00000100393 EP300 DLBCL 24127483
ENSG00000100393 EP300 DLBCL 24371765
ENSG00000100393 EP300 prostate cancer 24480624
ENSG00000100393 EP300 DLBCL 24529102
ENSG00000100393 EP300 tumours 24617454
ENSG00000100393 EP300 tumor 24622842
ENSG00000100393 EP300 skin cancers 24648447
ENSG00000100393 EP300 lung cancer 24746574
ENSG00000100393 EP300 colon cancer 24948597
ENSG00000100393 EP300 tumors 25123191
ENSG00000100393 EP300 tumor 25154636
ENSG00000100393 EP300 HNSCC 25275298
ENSG00000100393 EP300 cancer 25403569
ENSG00000100393 EP300 tumors 25444907
ENSG00000100393 EP300 cancer 25473433
ENSG00000100393 EP300 tumor 25520040
ENSG00000100393 EP300 DLBCL 25671298
ENSG00000100393 EP300 DLBCL 25723320
ENSG00000100393 EP300 cancer 25883651
ENSG00000100393 EP300 colorectal cancer 25919696
ENSG00000100393 EP300 HNSCC 26057471
ENSG00000100393 EP300 cancer 26087898
ENSG00000100393 EP300 squamous cell cancer 26134262
ENSG00000100393 EP300 metastatic tumors 26159519
ENSG00000100393 EP300 tumor 26192917
ENSG00000100393 EP300 breast cancer 26282201
ENSG00000100393 EP300 cancer 26325386
ENSG00000100393 EP300 DLBCL 26473533
ENSG00000100393 EP300 cancer 26503545
ENSG00000100393 EP300 Cancer 26556859
ENSG00000100393 EP300 breast cancer 26573761
ENSG00000100393 EP300 cancer 26603525
ENSG00000100393 EP300 tumors 26625313
ENSG00000100393 EP300 DLBCL 26654227
ENSG00000100393 EP300 cancer 26684240
ENSG00000100393 EP300 tumors 26731516
ENSG00000100393 EP300 tumors 26764183
ENSG00000100393 EP300 cancer 26796307
ENSG00000100393 EP300 tumors 26873401
ENSG00000100393 EP300 oral cancer 26980735
ENSG00000100393 EP300 thyroid cancer 27010584
ENSG00000100393 EP300 tumor 27043210
ENSG00000100393 EP300 tumors 27056325
ENSG00000100393 EP300 tumor 27158780
ENSG00000100393 EP300 cancer 27285761
ENSG00000100393 EP300 pancreatic cancer 27322077
ENSG00000100393 EP300 cervical cancer 27447860
ENSG00000100393 EP300 Tumor 27466623
ENSG00000100393 EP300 triple-negative breast cancer 27491809
ENSG00000100393 EP300 breast cancer 27539025
ENSG00000100393 EP300 cancer 27590521
ENSG00000100393 EP300 cancer 27633132
ENSG00000100393 EP300 cancer 27682507
ENSG00000100393 EP300 bladder tumors 27699256
ENSG00000100393 EP300 Cancer 27881443
ENSG00000100393 EP300 cancer 27903272
ENSG00000100393 EP300 AML 28100030
ENSG00000100393 EP300 gastric cancer 28169308
ENSG00000100393 EP300 cancer 28194033
ENSG00000100393 EP300 tumor 28251929
ENSG00000100393 EP300 gastric cancer 28260048
ENSG00000100393 EP300 lung cancer 28296173
ENSG00000100393 EP300 DLBCL 28302137
ENSG00000100393 EP300 tumor 28337291
ENSG00000100393 EP300 breast cancer 28341962
ENSG00000100393 EP300 tongue cancer 28356939
ENSG00000100393 EP300 cervical cancer 28390392
ENSG00000100393 EP300 colorectal cancer 28465257
ENSG00000100393 EP300 prostate cancer 28486411
ENSG00000100393 EP300 tumor 28551630
ENSG00000100393 EP300 colorectal cancer 28586030
ENSG00000100393 EP300 lung cancer 28592245
ENSG00000100393 EP300 Cancer 28744403
ENSG00000100393 EP300 lung cancer 28794006
ENSG00000100393 EP300 tumors 28804123
ENSG00000100393 EP300 tumor 28831000
ENSG00000100393 EP300 Cancer 28893800
ENSG00000100393 EP300 tumor 28915719
ENSG00000100393 EP300 ovarian cancer 28928801
ENSG00000100393 EP300 cancers 28938536
ENSG00000100393 EP300 Cancer 28970362
ENSG00000100393 EP300 cancer 29036683
ENSG00000100393 EP300 oral cancer 29037125
ENSG00000100393 EP300 colon cancer 29049411
ENSG00000100393 EP300 gastric cancer 29075795
ENSG00000100393 EP300 tumor 29084603
ENSG00000100393 EP300 colon tumors 29151923
ENSG00000100393 EP300 tumor 29305415
ENSG00000100393 EP300 Tumour 29305809
ENSG00000100393 EP300 cancer 29313809
ENSG00000100393 EP300 tumors 29359884
ENSG00000100393 EP300 cancer 29371938
ENSG00000100393 EP300 tumor 29442054
ENSG00000100393 EP300 prostate cancer 29448139
ENSG00000100393 EP300 pancreatic cancer 29464088
ENSG00000100393 EP300 tumor 29467311
ENSG00000100393 EP300 tumour 29531323
ENSG00000100393 EP300 prostate cancer 29536528
ENSG00000100393 EP300 breast cancer 29547932
ENSG00000100393 EP300 tumor 29572294
ENSG00000100393 EP300 cervical cancer 29623014
ENSG00000100393 EP300 cancers 29879950
ENSG00000100393 EP300 cancer 29884215
ENSG00000100393 EP300 DLBCL 29895903
ENSG00000100393 EP300 breast cancer 29927945
ENSG00000100393 EP300 prostate cancer 29970661
ENSG00000100393 EP300 cancer 30053266
ENSG00000100393 EP300 breast cancer 30093977
ENSG00000100393 EP300 cancers 30104217
ENSG00000100393 EP300 cancer 30119248
ENSG00000100393 EP300 tumor 30130555
ENSG00000100393 EP300 breast cancer 30132219
ENSG00000100393 EP300 tumor 30134235
ENSG00000100393 EP300 tongue cancer 30135512
ENSG00000100393 EP300 breast cancer 30250924
ENSG00000100393 EP300 prostate cancer 30255424
ENSG00000100393 EP300 tumor 30307363
ENSG00000100393 EP300 breast cancer 30314513
ENSG00000100393 EP300 cancer 30405107
ENSG00000100393 EP300 tumor 30514397
ENSG00000100393 EP300 gastric cancers 30514953
ENSG00000100393 EP300 cancers 30563911
ENSG00000100393 EP300 tumor 30570744
ENSG00000100393 EP300 cancer 30598101
ENSG00000100393 EP300 Breast Cancer 30606771
ENSG00000100393 EP300 tumors 30723478
ENSG00000100393 EP300 cancer 30760718
ENSG00000100393 EP300 CNS tumors 30816933
ENSG00000100393 EP300 breast cancer 30862505
ENSG00000100393 EP300 Tumor 30943407
ENSG00000100393 EP300 tumor 31010895
ENSG00000100393 EP300 tumors 31093971
ENSG00000100393 EP300 prostate cancer 31097763
ENSG00000100393 EP300 tumours 31164688
ENSG00000100393 EP300 tumor 31221981
ENSG00000100393 EP300 Breast Cancer 31357743
ENSG00000100393 EP300 tumors 31422218
ENSG00000100393 EP300 cancer 31476386
ENSG00000100393 EP300 cancer 31501464
ENSG00000100393 EP300 DLBCL 31519498
ENSG00000100393 EP300 tumor 31559120
ENSG00000100393 EP300 Breast Cancer 31614656
ENSG00000100393 EP300 tumor 31632486
ENSG00000100393 EP300 tumor 31901979
ENSG00000100393 EP300 cancer PMC5510248
Ensembl ID Gene symbol Disease/phenotype Mutation type Mutated / Total samples Literature
ENSG00000100393 EP300 colorectal adenocarcinoma missense_variant 6.147% (97/1578) 6 entries
ENSG00000100393 EP300 esophageal squamous cell carcinoma missense_variant 9.544% (90/943) 6 entries
ENSG00000100393 EP300 urothelial carcinoma stop_gained 13.95% (12/86) 1 entry
ENSG00000100393 EP300 urothelial carcinoma frameshift_variant 13.95% (12/86) 1 entry
ENSG00000100393 EP300 myelodysplastic syndrome stop_gained 23.5% (47/200) 1 entry
ENSG00000100393 EP300 colon adenocarcinoma missense_variant 5.957% (80/1343) 8 entries
ENSG00000100393 EP300 cecum adenocarcinoma frameshift_variant 8.889% (24/270) 1 entry
ENSG00000100393 EP300 esophageal squamous cell carcinoma frameshift_variant 9.544% (90/943) 3 entries
ENSG00000100393 EP300 colorectal adenocarcinoma frameshift_variant 6.147% (97/1578) 5 entries
ENSG00000100393 EP300 bladder carcinoma missense_variant 11.87% (68/573) 1 entry
ENSG00000100393 EP300 bladder transitional cell carcinoma conservative_inframe_deletion 12.35% (73/591) 1 entry
ENSG00000100393 EP300 myelodysplastic syndrome missense_variant 23.5% (47/200) 3 entries
ENSG00000100393 EP300 colorectal adenocarcinoma stop_gained 6.147% (97/1578) 5 entries
ENSG00000100393 EP300 colorectal adenocarcinoma sequence_alteration 6.147% (97/1578) 3 entries
ENSG00000100393 EP300 lung carcinoma sequence_alteration 18.33% (22/120) 1 entry
ENSG00000100393 EP300 bladder transitional cell carcinoma frameshift_variant 12.35% (73/591) 3 entries
ENSG00000100393 EP300 bladder carcinoma stop_gained 11.87% (68/573) 1 entry
ENSG00000100393 EP300 esophageal squamous cell carcinoma stop_gained 9.544% (90/943) 4 entries
ENSG00000100393 EP300 melanoma missense_variant 13.1% (19/145) 3 entries
ENSG00000100393 EP300 esophageal squamous cell carcinoma sequence_alteration 9.544% (90/943) 4 entries
ENSG00000100393 EP300 esophageal squamous cell carcinoma conservative_inframe_deletion 9.544% (90/943) 2 entries
ENSG00000100393 EP300 bladder carcinoma conservative_inframe_deletion 11.87% (68/573) 1 entry
ENSG00000100393 EP300 lymphoid neoplasm stop_gained 13.71% (27/197) 1 entry
ENSG00000100393 EP300 bladder transitional cell carcinoma sequence_alteration 12.35% (73/591) 4 entries
ENSG00000100393 EP300 bladder carcinoma sequence_alteration 11.87% (68/573) 2 entries
ENSG00000100393 EP300 colon adenocarcinoma sequence_alteration 5.957% (80/1343) 2 entries
ENSG00000100393 EP300 myelodysplastic syndrome frameshift_variant 23.5% (47/200) 1 entry
ENSG00000100393 EP300 colon adenocarcinoma frameshift_variant 5.957% (80/1343) 6 entries
ENSG00000100393 EP300 colon adenocarcinoma stop_gained 5.957% (80/1343) 6 entries
ENSG00000100393 EP300 myelodysplastic syndrome conservative_inframe_deletion 23.5% (47/200) 1 entry
ENSG00000100393 EP300 bladder carcinoma frameshift_variant 11.87% (68/573) 2 entries
ENSG00000100393 EP300 bladder transitional cell carcinoma missense_variant 12.35% (73/591) 5 entries
ENSG00000100393 EP300 cecum adenocarcinoma stop_gained 8.889% (24/270) 1 entry
ENSG00000100393 EP300 bladder transitional cell carcinoma stop_gained 12.35% (73/591) 6 entries
ENSG00000100393 EP300 cecum adenocarcinoma sequence_alteration 8.889% (24/270) 1 entry
ENSG00000100393 EP300 urothelial carcinoma missense_variant 13.95% (12/86) 1 entry
ENSG00000100393 EP300 cecum adenocarcinoma missense_variant 8.889% (24/270) 3 entries
ENSG00000100393 EP300 HER2 Positive Breast Carcinoma missense_variant 4.787% (9/188) 4 entries
ENSG00000100393 EP300 urothelial carcinoma sequence_alteration 13.95% (12/86) 1 entry
ENSG00000100393 EP300 kidney Wilms tumor conservative_inframe_deletion 0.6173% (6/972) 1 entry
ENSG00000100393 EP300 T-cell acute lymphoblastic leukemia missense_variant 3.033% (30/989) 3 entries
ENSG00000100393 EP300 T-cell acute lymphoblastic leukemia conservative_inframe_deletion 3.033% (30/989) 2 entries
ENSG00000100393 EP300 pancreatic ductal adenocarcinoma missense_variant 1.966% (34/1729) 4 entries
ENSG00000100393 EP300 Anal Squamous Cell Carcinoma sequence_alteration 12.05% (10/83) 2 entries
ENSG00000100393 EP300 papillary renal cell carcinoma missense_variant 0.5155% (2/388) 1 entry
ENSG00000100393 EP300 gastric adenocarcinoma frameshift_variant 2.839% (27/951) 1 entry
ENSG00000100393 EP300 glioma stop_gained 0.487% (3/616) 2 entries
ENSG00000100393 EP300 marginal zone B-cell lymphoma missense_variant 9.756% (4/41) 2 entries
ENSG00000100393 EP300 bile duct adenocarcinoma missense_variant 0.8945% (5/559) 1 entry
ENSG00000100393 EP300 breast carcinoma sequence_alteration 1.918% (31/1616) 1 entry
ENSG00000100393 EP300 Ampulla of Vater Carcinoma missense_variant 2.353% (2/85) 1 entry
ENSG00000100393 EP300 T-cell acute lymphoblastic leukemia frameshift_variant 3.033% (30/989) 3 entries
ENSG00000100393 EP300 gastric adenocarcinoma missense_variant 2.839% (27/951) 3 entries
ENSG00000100393 EP300 prostate adenocarcinoma missense_variant 3.03% (67/2211) 3 entries
ENSG00000100393 EP300 Merkel cell skin cancer missense_variant 5.263% (5/95) 2 entries
ENSG00000100393 EP300 renal cell carcinoma frameshift_variant 5.882% (4/68) 1 entry
ENSG00000100393 EP300 head and neck squamous cell carcinoma sequence_alteration 2.937% (22/749) 1 entry
ENSG00000100393 EP300 lung adenocarcinoma frameshift_variant 2.128% (57/2679) 2 entries
ENSG00000100393 EP300 breast carcinoma frameshift_variant 1.918% (31/1616) 1 entry
ENSG00000100393 EP300 hepatocellular carcinoma missense_variant 1.52% (15/987) 2 entries
ENSG00000100393 EP300 basal cell carcinoma missense_variant 10.29% (7/68) 1 entry
ENSG00000100393 EP300 female breast carcinoma missense_variant 2.244% (9/401) 1 entry
ENSG00000100393 EP300 melanoma sequence_alteration 13.1% (19/145) 1 entry
ENSG00000100393 EP300 brain glioblastoma sequence_alteration 0.898% (11/1225) 1 entry
ENSG00000100393 EP300 Gallbladder Adenocarcinoma sequence_alteration 1.571% (3/191) 1 entry
ENSG00000100393 EP300 skin melanoma stop_gained 3.442% (40/1162) 1 entry
ENSG00000100393 EP300 Cervical Small Cell Carcinoma missense_variant 25.0% (2/8) 1 entry
ENSG00000100393 EP300 oral squamous cell carcinoma missense_variant 4.114% (13/316) 9 entries
ENSG00000100393 EP300 adenosquamous lung carcinoma missense_variant 13.64% (3/22) 2 entries
ENSG00000100393 EP300 nasopharyngeal squamous cell carcinoma stop_gained 2.922% (9/308) 1 entry
ENSG00000100393 EP300 chronic myelomonocytic leukemia missense_variant 6.818% (6/88) 1 entry
ENSG00000100393 EP300 acute myeloid leukemia frameshift_variant 1.596% (42/2631) 3 entries
ENSG00000100393 EP300 Anal Squamous Cell Carcinoma missense_variant 12.05% (10/83) 2 entries
ENSG00000100393 EP300 rectal adenocarcinoma conservative_inframe_deletion 2.545% (14/550) 1 entry
ENSG00000100393 EP300 cervical squamous cell carcinoma missense_variant 6.154% (20/325) 1 entry
ENSG00000100393 EP300 dedifferentiated liposarcoma missense_variant 4.444% (2/45) 1 entry
ENSG00000100393 EP300 esophageal adenocarcinoma missense_variant 4.015% (22/548) 2 entries
ENSG00000100393 EP300 pharyngeal squamous cell carcinoma stop_gained 6.993% (10/143) 1 entry
ENSG00000100393 EP300 lung adenocarcinoma sequence_alteration 2.128% (57/2679) 1 entry
ENSG00000100393 EP300 rectal adenocarcinoma missense_variant 2.545% (14/550) 3 entries
ENSG00000100393 EP300 gastric intestinal type adenocarcinoma missense_variant 5.102% (5/98) 2 entries
ENSG00000100393 EP300 small cell lung carcinoma missense_variant 6.843% (31/453) 4 entries
ENSG00000100393 EP300 pleomorphic liposarcoma frameshift_variant 33.33% (3/9) 2 entries
ENSG00000100393 EP300 diffuse large B-cell lymphoma missense_variant 5.164% (30/581) 7 entries
ENSG00000100393 EP300 breast carcinoma missense_variant 1.918% (31/1616) 4 entries
ENSG00000100393 EP300 T-cell acute lymphoblastic leukemia amino_acid_insertion 3.033% (30/989) 2 entries
ENSG00000100393 EP300 endometrial carcinoma missense_variant 7.143% (5/70) 2 entries
ENSG00000100393 EP300 acute myeloid leukemia missense_variant 1.596% (42/2631) 2 entries
ENSG00000100393 EP300 Endometrial Endometrioid Adenocarcinoma stop_gained 5.538% (36/650) 1 entry
ENSG00000100393 EP300 hemangioblastoma sequence_alteration 11.43% (4/35) 1 entry
ENSG00000100393 EP300 salivary gland adenoid cystic carcinoma frameshift_variant 4.688% (3/64) 2 entries
ENSG00000100393 EP300 breast ductal adenocarcinoma sequence_alteration 3.002% (48/1599) 1 entry
ENSG00000100393 EP300 acute myeloid leukemia sequence_alteration 1.596% (42/2631) 1 entry
ENSG00000100393 EP300 Pleural Mesothelioma missense_variant 1.399% (2/143) 2 entries
ENSG00000100393 EP300 undifferentiated pleomorphic sarcoma missense_variant 3.226% (2/62) 1 entry
ENSG00000100393 EP300 osteosarcoma missense_variant 1.316% (2/152) 1 entry
ENSG00000100393 EP300 acute lymphoblastic leukemia missense_variant 0.9547% (4/419) 1 entry
ENSG00000100393 EP300 ovarian carcinoma frameshift_variant 1.98% (4/202) 2 entries
ENSG00000100393 EP300 anaplastic astrocytoma missense_variant 2.158% (3/139) 2 entries
ENSG00000100393 EP300 mucosal melanoma missense_variant 2.857% (2/70) 2 entries
ENSG00000100393 EP300 Endometrial Endometrioid Adenocarcinoma frameshift_variant 5.538% (36/650) 2 entries
ENSG00000100393 EP300 central nervous system primitive neuroectodermal neoplasm missense_variant 1.116% (5/448) 2 entries
ENSG00000100393 EP300 melanoma conservative_inframe_deletion 13.1% (19/145) 1 entry
ENSG00000100393 EP300 prostate adenocarcinoma sequence_alteration 3.03% (67/2211) 1 entry
ENSG00000100393 EP300 papillary thyroid carcinoma missense_variant 1.217% (6/493) 1 entry
ENSG00000100393 EP300 prostate carcinoma sequence_alteration 2.474% (12/485) 1 entry
ENSG00000100393 EP300 gastric adenocarcinoma sequence_alteration 2.839% (27/951) 1 entry
ENSG00000100393 EP300 pancreatic neuroendocrine tumor missense_variant 2.119% (5/236) 1 entry
ENSG00000100393 EP300 central nervous system primitive neuroectodermal neoplasm sequence_alteration 1.116% (5/448) 1 entry
ENSG00000100393 EP300 neoplasm of mature B-cells missense_variant 10.19% (11/108) 4 entries
ENSG00000100393 EP300 diffuse large B-cell lymphoma frameshift_variant 5.164% (30/581) 1 entry
ENSG00000100393 EP300 Splenic Diffuse Large B-Cell Lymphoma missense_variant 50.0% (2/4) 2 entries
ENSG00000100393 EP300 Gastrointestinal stromal tumor missense_variant 1.316% (2/152) 1 entry
ENSG00000100393 EP300 skin melanoma missense_variant 3.442% (40/1162) 5 entries
ENSG00000100393 EP300 clear cell renal carcinoma missense_variant 0.805% (13/1615) 2 entries
ENSG00000100393 EP300 acute myeloid leukemia stop_gained 1.596% (42/2631) 2 entries
ENSG00000100393 EP300 neoplasm of mature B-cells sequence_alteration 10.19% (11/108) 1 entry
ENSG00000100393 EP300 esophageal squamous cell carcinoma stop_lost 9.544% (90/943) 1 entry
ENSG00000100393 EP300 head and neck squamous cell carcinoma stop_gained 2.937% (22/749) 2 entries
ENSG00000100393 EP300 pharyngeal squamous cell carcinoma missense_variant 6.993% (10/143) 3 entries
ENSG00000100393 EP300 Dysplasia in Ulcerative Colitis missense_variant 25.0% (2/8) 1 entry
ENSG00000100393 EP300 nasopharyngeal squamous cell carcinoma missense_variant 2.922% (9/308) 3 entries
ENSG00000100393 EP300 T-cell acute lymphoblastic leukemia sequence_alteration 3.033% (30/989) 3 entries
ENSG00000100393 EP300 diffuse large B-cell lymphoma stop_gained 5.164% (30/581) 2 entries
ENSG00000100393 EP300 prostate adenocarcinoma stop_gained 3.03% (67/2211) 1 entry
ENSG00000100393 EP300 head and neck squamous cell carcinoma missense_variant 2.937% (22/749) 3 entries
ENSG00000100393 EP300 squamous cell lung carcinoma missense_variant 3.176% (33/1039) 6 entries
ENSG00000100393 EP300 Breast Carcinoma by Gene Expression Profile missense_variant 4.167% (4/96) 2 entries
ENSG00000100393 EP300 lung adenocarcinoma missense_variant 2.128% (57/2679) 9 entries
ENSG00000100393 EP300 chronic lymphocytic leukemia missense_variant 1.483% (14/944) 3 entries
ENSG00000100393 EP300 T-cell acute lymphoblastic leukemia stop_gained 3.033% (30/989) 3 entries
ENSG00000100393 EP300 breast ductal adenocarcinoma missense_variant 3.002% (48/1599) 2 entries
ENSG00000100393 EP300 non-small cell lung carcinoma missense_variant 2.609% (3/115) 1 entry
ENSG00000100393 EP300 ovarian serous adenocarcinoma missense_variant 0.5931% (5/843) 1 entry
ENSG00000100393 EP300 anaplastic oligodendroglioma missense_variant 3.297% (3/91) 1 entry
ENSG00000100393 EP300 small cell lung carcinoma sequence_alteration 6.843% (31/453) 2 entries
ENSG00000100393 EP300 breast carcinoma stop_gained 1.918% (31/1616) 1 entry
ENSG00000100393 EP300 brain glioblastoma missense_variant 0.898% (11/1225) 2 entries
ENSG00000100393 EP300 neoplasm of mature B-cells conservative_inframe_deletion 10.19% (11/108) 2 entries
ENSG00000100393 EP300 Endometrial Endometrioid Adenocarcinoma missense_variant 5.538% (36/650) 2 entries
ENSG00000100393 EP300 diffuse large B-cell lymphoma sequence_alteration 5.164% (30/581) 2 entries
ENSG00000100393 EP300 Thyroid Gland Undifferentiated (Anaplastic) Carcinoma stop_gained 1.901% (5/263) 2 entries
ENSG00000100393 EP300 Endometrial Clear Cell Adenocarcinoma missense_variant 6.25% (4/64) 3 entries
ENSG00000100393 EP300 prostate carcinoma missense_variant 2.474% (12/485) 4 entries
ENSG00000100393 EP300 breast ductal adenocarcinoma stop_gained 3.002% (48/1599) 1 entry
ENSG00000100393 EP300 lung adenocarcinoma stop_gained 2.128% (57/2679) 4 entries
ENSG00000100393 EP300 polycythemia vera frameshift_variant 0.7634% (1/131) 1 entry
ENSG00000100393 EP300 metaplastic breast carcinoma missense_variant 3.333% (2/60) 1 entry
ENSG00000100393 EP300 basal cell carcinoma stop_gained 10.29% (7/68) 1 entry
ENSG00000100393 EP300 Pancreatic Acinar Cell Carcinoma missense_variant 2.941% (1/34) 1 entry
ENSG00000100393 EP300 anaplastic astrocytoma stop_gained 2.158% (3/139) 1 entry
ENSG00000100393 EP300 Parotid Gland Acinic Cell Carcinoma missense_variant 100.0% (1/1) 1 entry
ENSG00000100393 EP300 acute lymphoblastic leukemia frameshift_variant 0.9547% (4/419) 1 entry
ENSG00000100393 EP300 ependymoma conservative_inframe_deletion 1.852% (1/54) 1 entry
ENSG00000100393 EP300 colon carcinoma frameshift_variant 25.0% (2/8) 1 entry
ENSG00000100393 EP300 leiomyoma missense_variant 50.0% (1/2) 1 entry
ENSG00000100393 EP300 adrenal cortex carcinoma sequence_alteration 0.9174% (2/218) 1 entry
ENSG00000100393 EP300 diffuse large B-cell lymphoma conservative_inframe_deletion 5.164% (30/581) 1 entry
ENSG00000100393 EP300 lung carcinoid tumor missense_variant 3.704% (1/27) 1 entry
ENSG00000100393 EP300 esophageal adenocarcinoma stop_gained 4.015% (22/548) 1 entry
ENSG00000100393 EP300 Central Nervous System Lymphoma missense_variant 11.11% (1/9) 1 entry
ENSG00000100393 EP300 skin melanoma frameshift_variant 3.442% (40/1162) 1 entry
ENSG00000100393 EP300 ulcerative colitis missense_variant 11.11% (1/9) 1 entry
ENSG00000100393 EP300 desmoplastic small round cell tumor stop_gained 4.545% (1/22) 1 entry
ENSG00000100393 EP300 pharyngeal squamous cell carcinoma frameshift_variant 6.993% (10/143) 1 entry
ENSG00000100393 EP300 salivary gland carcinoma missense_variant 3.03% (1/33) 1 entry
ENSG00000100393 EP300 Malignant Germ Cell Tumor missense_variant 0.5525% (1/181) 1 entry
ENSG00000100393 EP300 gastric intestinal type adenocarcinoma conservative_inframe_deletion 5.102% (5/98) 1 entry
ENSG00000100393 EP300 skin carcinoma missense_variant 5.769% (6/104) 1 entry
ENSG00000100393 EP300 squamous cell lung carcinoma stop_gained 3.176% (33/1039) 1 entry
ENSG00000100393 EP300 renal cell carcinoma missense_variant 5.882% (4/68) 1 entry
ENSG00000100393 EP300 laryngeal squamous cell carcinoma missense_variant 2.439% (1/41) 1 entry
ENSG00000100393 EP300 endometrium adenocarcinoma frameshift_variant 2.941% (1/34) 1 entry
ENSG00000100393 EP300 Vulvar Squamous Cell Carcinoma stop_gained 5.263% (1/19) 1 entry
ENSG00000100393 EP300 gastric intestinal type adenocarcinoma sequence_alteration 5.102% (5/98) 1 entry
ENSG00000100393 EP300 head and neck squamous cell carcinoma frameshift_variant 2.937% (22/749) 1 entry
ENSG00000100393 EP300 nasopharyngeal squamous cell carcinoma frameshift_variant 2.922% (9/308) 1 entry
ENSG00000100393 EP300 lobular breast carcinoma missense_variant 0.4219% (1/237) 1 entry
ENSG00000100393 EP300 glioma missense_variant 0.487% (3/616) 1 entry
ENSG00000100393 EP300 ovarian carcinoma stop_gained 1.98% (4/202) 1 entry
ENSG00000100393 EP300 brain glioblastoma frameshift_variant 0.898% (11/1225) 1 entry
ENSG00000100393 EP300 ovarian serous adenocarcinoma stop_gained 0.5931% (5/843) 1 entry
ENSG00000100393 EP300 ovarian adenocarcinoma missense_variant 10.0% (1/10) 1 entry
ENSG00000100393 EP300 angioimmunoblastic T-cell lymphoma conservative_inframe_deletion 3.738% (4/107) 1 entry
ENSG00000100393 EP300 oral squamous cell carcinoma stop_gained 4.114% (13/316) 1 entry
ENSG00000100393 EP300 Uterine Carcinosarcoma missense_variant 1.351% (2/148) 1 entry
ENSG00000100393 EP300 Thyroid Gland Undifferentiated (Anaplastic) Carcinoma frameshift_variant 1.901% (5/263) 1 entry
ENSG00000100393 EP300 kidney Wilms tumor frameshift_variant 0.6173% (6/972) 1 entry
ENSG00000100393 EP300 small intestinal adenocarcinoma frameshift_variant 9.524% (2/21) 1 entry
ENSG00000100393 EP300 Cervical Adenosquamous Carcinoma frameshift_variant 20.0% (1/5) 1 entry
ENSG00000100393 EP300 bronchoalveolar adenocarcinoma missense_variant 4.545% (1/22) 1 entry
ENSG00000100393 EP300 Parotid Gland Adenoid Cystic Carcinoma stop_gained 7.692% (1/13) 1 entry
ENSG00000100393 EP300 marginal zone B-cell lymphoma conservative_inframe_deletion 9.756% (4/41) 1 entry
ENSG00000100393 EP300 Parathyroid Gland Carcinoma stop_gained 2.857% (1/35) 1 entry
ENSG00000100393 EP300 angioimmunoblastic T-cell lymphoma missense_variant 3.738% (4/107) 1 entry
ENSG00000100393 EP300 Pleural Epithelioid Mesothelioma missense_variant 0.9756% (2/205) 1 entry
ENSG00000100393 EP300 salivary gland squamous cell carcinoma missense_variant 50.0% (1/2) 1 entry
ENSG00000100393 EP300 bile duct adenocarcinoma stop_gained 0.8945% (5/559) 1 entry
ENSG00000100393 EP300 vulvar intraepithelial neoplasia missense_variant 9.091% (1/11) 1 entry
ENSG00000100393 EP300 angioimmunoblastic T-cell lymphoma stop_gained 3.738% (4/107) 1 entry
ENSG00000100393 EP300 gastric intestinal type adenocarcinoma frameshift_variant 5.102% (5/98) 1 entry
ENSG00000100393 EP300 nasopharyngeal squamous cell carcinoma sequence_alteration 2.922% (9/308) 1 entry
ENSG00000100393 EP300 Conjunctival Melanoma missense_variant 25.0% (1/4) 1 entry
ENSG00000100393 EP300 large cell lung carcinoma sequence_alteration 4.167% (1/24) 1 entry
ENSG00000100393 EP300 meningioma (disease) frameshift_variant 1.37% (1/73) 1 entry
ENSG00000100393 EP300 Merkel cell skin cancer sequence_alteration 5.263% (5/95) 1 entry
ENSG00000100393 EP300 neoplasm missense_variant 3.333% (1/30) 1 entry
ENSG00000100393 EP300 breast ductal adenocarcinoma frameshift_variant 3.002% (48/1599) 1 entry
ENSG00000100393 EP300 Anal Squamous Cell Carcinoma stop_gained 12.05% (10/83) 1 entry
ENSG00000100393 EP300 angioimmunoblastic T-cell lymphoma sequence_alteration 3.738% (4/107) 1 entry
ENSG00000100393 EP300 bile duct adenocarcinoma frameshift_variant 0.8945% (5/559) 1 entry
ENSG00000100393 EP300 chronic myelomonocytic leukemia conservative_inframe_deletion 6.818% (6/88) 1 entry
ENSG00000100393 EP300 testicular seminoma missense_variant 2.564% (2/78) 1 entry
ENSG00000100393 EP300 Bladder Squamous Cell Carcinoma missense_variant 50.0% (1/2) 1 entry
ENSG00000100393 EP300 small cell lung carcinoma frameshift_variant 6.843% (31/453) 1 entry
ENSG00000100393 EP300 astrocytoma missense_variant 16.67% (1/6) 1 entry
ENSG00000100393 EP300 rectal adenocarcinoma sequence_alteration 2.545% (14/550) 1 entry
ENSG00000100393 EP300 pleomorphic liposarcoma missense_variant 33.33% (3/9) 1 entry
ENSG00000100393 EP300 small intestinal adenocarcinoma missense_variant 9.524% (2/21) 1 entry
ENSG00000100393 EP300 Thymic Squamous Cell Carcinoma sequence_alteration 7.407% (2/27) 1 entry
ENSG00000100393 EP300 hemangioblastoma missense_variant 11.43% (4/35) 1 entry
ENSG00000100393 EP300 esophageal adenocarcinoma frameshift_variant 4.015% (22/548) 1 entry
ENSG00000100393 EP300 salivary gland adenoid cystic carcinoma sequence_alteration 4.688% (3/64) 1 entry
ENSG00000100393 EP300 head and neck squamous cell carcinoma conservative_inframe_deletion 2.937% (22/749) 1 entry
ENSG00000100393 EP300 Duodenal Adenocarcinoma missense_variant 5.882% (1/17) 1 entry
ENSG00000100393 EP300 testicular seminoma stop_gained 2.564% (2/78) 1 entry
ENSG00000100393 EP300 colon carcinoma stop_gained 25.0% (2/8) 1 entry
ENSG00000100393 EP300 papillary thyroid carcinoma stop_gained 1.217% (6/493) 1 entry
ENSG00000100393 EP300 primary peritoneal carcinoma (disease) missense_variant 100.0% (1/1) 1 entry
ENSG00000100393 EP300 prostate adenocarcinoma conservative_inframe_deletion 3.03% (67/2211) 1 entry
ENSG00000100393 EP300 bile duct adenocarcinoma conservative_inframe_deletion 0.8945% (5/559) 1 entry
ENSG00000100393 EP300 adrenal cortex carcinoma missense_variant 0.9174% (2/218) 1 entry
ENSG00000100393 EP300 cervical carcinoma frameshift_variant 8.696% (2/23) 1 entry
ENSG00000100393 EP300 Thyroid Gland Undifferentiated (Anaplastic) Carcinoma sequence_alteration 1.901% (5/263) 1 entry
ENSG00000100393 EP300 B-cell acute lymphoblastic leukemia missense_variant 0.6329% (1/158) 1 entry
ENSG00000100393 EP300 Ocular Sebaceous Carcinoma missense_variant 4.348% (1/23) 1 entry
ENSG00000100393 EP300 Burkitts lymphoma stop_gained 1.235% (1/81) 1 entry
ENSG00000100393 EP300 anaplastic oligodendroglioma sequence_alteration 3.297% (3/91) 1 entry
ENSG00000100393 EP300 Pleural Epithelioid Mesothelioma sequence_alteration 0.9756% (2/205) 1 entry
ENSG00000100393 EP300 Thymic Squamous Cell Carcinoma frameshift_variant 7.407% (2/27) 1 entry
ENSG00000100393 EP300 solitary fibrous tumor missense_variant 3.448% (1/29) 1 entry
ENSG00000100393 EP300 cervical carcinoma missense_variant 8.696% (2/23) 1 entry
ENSG00000100393 EP300 small cell lung carcinoma conservative_inframe_deletion 6.843% (31/453) 1 entry
ENSG00000100393 EP300 leiomyosarcoma missense_variant 0.9901% (1/101) 1 entry
ENSG00000100393 EP300 acute lymphoblastic leukemia sequence_alteration 0.9547% (4/419) 1 entry
ENSG00000100393 EP300 gastric adenocarcinoma stop_gained 2.839% (27/951) 1 entry
ENSG00000100393 EP300 pancreatic ductal adenocarcinoma stop_gained 1.966% (34/1729) 1 entry
Ensembl ID Gene symbol Cancer P-value Which worse show
ENSG00000100393 EP300 UVM 0.0022 high
ENSG00000100393 EP300 PAAD 0.02 high
ENSG00000100393 EP300 ACC 0.045 high
ENSG00000100393 EP300 HNSC 0.045 low
ENSG00000100393 EP300 READ 0.011 low
ENSG00000100393 EP300 KIRP 0.016 high
ENSG00000100393 EP300 KICH 0.036 low
ENSG00000100393 EP300 ESCA 0.044 low
ENSG00000100393 EP300 BLCA 0.04 high
ENSG00000100393 EP300 GBM 0.0046 low
ENSG00000100393 EP300 CESC 0.047 low
ENSG00000100393 EP300 LIHC 0.022 high
Ensembl ID Gene symbol Cancer CNV type -log10(q-value) G-score average amplitude frequency
ENSG00000100393 EP300 CESC Del 0.667684 0.066060 0.361245 0.267797
ENSG00000100393 EP300 SKCM Amp 7.992589 0.314000 0.702499 0.414169
ENSG00000100393 EP300 PCPG Del 0.811297 0.060816 0.620953 0.401235
ENSG00000100393 EP300 BLCA Del 3.204682 0.114103 0.371169 0.458333
ENSG00000100393 EP300 UCEC Del 1.148590 0.053831 0.548851 0.222635
ENSG00000100393 EP300 OV Del 7.571561 0.275805 0.657482 0.820380